IL264873A - - Google Patents
Info
- Publication number
- IL264873A IL264873A IL26487319A IL26487319A IL264873A IL 264873 A IL264873 A IL 264873A IL 26487319 A IL26487319 A IL 26487319A IL 26487319 A IL26487319 A IL 26487319A IL 264873 A IL264873 A IL 264873A
- Authority
- IL
- Israel
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
- C12N9/2402—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
- C12N9/2405—Glucanases
- C12N9/2434—Glucanases acting on beta-1,4-glucosidic bonds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2887—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P21/00—Preparation of peptides or proteins
- C12P21/005—Glycopeptides, glycoproteins
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
- C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
- C12Y302/01096—Mannosyl-glycoprotein endo-beta-N-acetylglucosaminidase (3.2.1.96)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
- C07K2317/41—Glycosylation, sialylation, or fucosylation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/72—Increased effector function due to an Fc-modification
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
- C07K2319/21—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a His-tag
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- General Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biomedical Technology (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Enzymes And Modification Thereof (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662378806P | 2016-08-24 | 2016-08-24 | |
| PCT/US2017/048252 WO2018039373A1 (en) | 2016-08-24 | 2017-08-23 | Endoglycosidase mutants for glycoprotein remodeling and methods of using it |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| IL264873A true IL264873A (de) | 2019-04-30 |
| IL264873B1 IL264873B1 (en) | 2023-04-01 |
| IL264873B2 IL264873B2 (en) | 2023-08-01 |
Family
ID=61241785
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL264873A IL264873B2 (en) | 2016-08-24 | 2019-02-17 | Endoglycosidase mutants for glycoprotein remodeling and methods of using them |
Country Status (10)
| Country | Link |
|---|---|
| US (2) | US10000747B2 (de) |
| EP (1) | EP3532090B1 (de) |
| JP (1) | JP6965350B2 (de) |
| KR (1) | KR102166120B1 (de) |
| CN (1) | CN110234341A (de) |
| AU (1) | AU2017315677B2 (de) |
| CA (1) | CA3034876C (de) |
| IL (1) | IL264873B2 (de) |
| TW (3) | TWI727884B (de) |
| WO (1) | WO2018039373A1 (de) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10023892B2 (en) * | 2014-05-27 | 2018-07-17 | Academia Sinica | Compositions and methods relating to universal glycoforms for enhanced antibody efficacy |
| US20150344585A1 (en) | 2014-05-27 | 2015-12-03 | Academia Sinica | Anti-cd20 glycoantibodies and uses thereof |
| TWI895275B (zh) * | 2019-08-05 | 2025-09-01 | 醣基生醫股份有限公司 | 用於重塑抗體醣型之融合蛋白 |
| TW202227479A (zh) * | 2020-09-02 | 2022-07-16 | 日商第一三共股份有限公司 | 新穎內－β－Ｎ－乙醯葡萄糖胺苷酶 |
| CA3208429A1 (en) * | 2021-03-08 | 2022-09-15 | Venn Biosciences Corporation | Biomarkers for determining an immuno-oncology response |
| WO2022241054A1 (en) * | 2021-05-11 | 2022-11-17 | Northeastern University | Site-specific modification of glycoproteins through transglutaminase-mediated conjugation |
| AR126089A1 (es) | 2021-06-07 | 2023-09-13 | Amgen Inc | Uso de fucosidasa para controlar el nivel de afucosilación de proteínas glucosiladas |
| CA3253428A1 (en) | 2022-03-02 | 2025-06-16 | Daiichi Sankyo Company, Limited | PROCESS FOR PRODUCING A MOLECULE CONTAINING Fc |
| WO2023232144A1 (zh) | 2022-06-02 | 2023-12-07 | 启德医药科技（苏州）有限公司 | 寡糖连接子，包含寡糖连接子的连接子-负载物和糖链重塑的抗体偶联药物，其制备方法和用途 |
| KR20250031198A (ko) | 2022-07-01 | 2025-03-06 | 진콴텀 헬스케어 (쑤저우) 씨오., 엘티디. | 고정화된 엔도글리코시다아제 융합 단백질 및 이의 적용 |
| WO2024220732A1 (en) * | 2023-04-18 | 2024-10-24 | Emory University | Endoglycosidase s2 (endos2) mutants and uses thereof |
| CN117165643B (zh) * | 2023-08-17 | 2025-10-28 | 山东大学 | 一种糖苷内切酶在水解高甘露糖型n-糖蛋白中的应用 |
| CN119709701A (zh) * | 2023-09-28 | 2025-03-28 | 上海糖岭生物医药有限责任公司 | 糖苷内切酶s2突变体、其制备方法及其在抗体糖基化改造中的应用 |
| WO2025098484A1 (zh) * | 2023-11-10 | 2025-05-15 | 上海齐鲁制药研究中心有限公司 | 新型Endo S2突变体酶 |
| TW202540414A (zh) * | 2024-03-01 | 2025-10-16 | 大陸商上海齊魯製藥研究中心有限公司 | 新型Endo S2突變體酶 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201115841D0 (en) * | 2011-09-13 | 2011-10-26 | Genovis Ab | Protein and method |
| WO2013120066A1 (en) * | 2012-02-10 | 2013-08-15 | University Of Maryland, Baltimore | Chemoenzymatic glycoengineering of antibodies and fc fragments thereof |
| US20150344585A1 (en) * | 2014-05-27 | 2015-12-03 | Academia Sinica | Anti-cd20 glycoantibodies and uses thereof |
| JP6744738B2 (ja) * | 2015-06-29 | 2020-08-19 | 公益財団法人野口研究所 | グライコシンターゼ |
| JP2019501663A (ja) * | 2016-01-15 | 2019-01-24 | ユニバーシティー オブ メリーランド，カレッジ パーク | グリコシンターゼとしてのＥｎｄｏ−Ｓ２変異体、糖タンパク質の製造方法および糖タンパク質の糖鎖操作のための使用 |
-
2017
- 2017-08-23 TW TW109129407A patent/TWI727884B/zh active
- 2017-08-23 TW TW109129406A patent/TWI727883B/zh active
- 2017-08-23 AU AU2017315677A patent/AU2017315677B2/en active Active
- 2017-08-23 TW TW106128522A patent/TWI706035B/zh active
- 2017-08-23 US US15/684,897 patent/US10000747B2/en active Active
- 2017-08-23 CA CA3034876A patent/CA3034876C/en active Active
- 2017-08-23 CN CN201780051835.1A patent/CN110234341A/zh active Pending
- 2017-08-23 WO PCT/US2017/048252 patent/WO2018039373A1/en not_active Ceased
- 2017-08-23 KR KR1020197007861A patent/KR102166120B1/ko active Active
- 2017-08-23 EP EP17844364.4A patent/EP3532090B1/de active Active
- 2017-08-23 JP JP2019531870A patent/JP6965350B2/ja active Active
-
2018
- 2018-06-18 US US16/011,622 patent/US10407673B2/en active Active
-
2019
- 2019-02-17 IL IL264873A patent/IL264873B2/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| AU2017315677A1 (en) | 2019-04-11 |
| CA3034876A1 (en) | 2018-03-01 |
| IL264873B1 (en) | 2023-04-01 |
| TWI727884B (zh) | 2021-05-11 |
| TW202117012A (zh) | 2021-05-01 |
| TWI727883B (zh) | 2021-05-11 |
| EP3532090A4 (de) | 2021-01-13 |
| EP3532090A1 (de) | 2019-09-04 |
| TWI706035B (zh) | 2020-10-01 |
| JP6965350B2 (ja) | 2021-11-10 |
| CA3034876C (en) | 2022-10-04 |
| US20180298361A1 (en) | 2018-10-18 |
| AU2017315677B2 (en) | 2021-03-11 |
| WO2018039373A1 (en) | 2018-03-01 |
| US20180057804A1 (en) | 2018-03-01 |
| IL264873B2 (en) | 2023-08-01 |
| EP3532090B1 (de) | 2026-03-25 |
| TW201823455A (zh) | 2018-07-01 |
| KR20190039580A (ko) | 2019-04-12 |
| US10407673B2 (en) | 2019-09-10 |
| CN110234341A (zh) | 2019-09-13 |
| KR102166120B1 (ko) | 2020-10-16 |
| JP2020500549A (ja) | 2020-01-16 |
| TW202115251A (zh) | 2021-04-16 |
| US10000747B2 (en) | 2018-06-19 |